Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention
Gastric cancer is the second leading cause of cancer-related death worldwide. A meta-analysis of seven randomized controlled trials concluded that Helicobacter pylori eradication reduces gastric cancer incidence by 35%. Current consensus is that H. pylori screening and treatment is cost-effective on...
| Main Authors: | , |
|---|---|
| Format: | Journal Article |
| Published: |
2013
|
| Online Access: | http://hdl.handle.net/20.500.11937/49896 |
| _version_ | 1848758343969013760 |
|---|---|
| author | Lansdorp_Vogelaar, Iris Sharp, L. |
| author_facet | Lansdorp_Vogelaar, Iris Sharp, L. |
| author_sort | Lansdorp_Vogelaar, Iris |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Gastric cancer is the second leading cause of cancer-related death worldwide. A meta-analysis of seven randomized controlled trials concluded that Helicobacter pylori eradication reduces gastric cancer incidence by 35%. Current consensus is that H. pylori screening and treatment is cost-effective only in high-risk populations. This paper provides an up-to-date overview of the evidence for cost-effectiveness of H. pylori screening and treatment in different population settings and risk levels for H. pylori infection. Ten unique cost-effectiveness or cost-utility analyses were identified. All found that screening for H. pylori to prevent gastric cancer in the general population costs less than $50,000 per LYG. This finding was robust for differences in H. pylori prevalence, gender and ethnicity. Based on limited evidence, re-treatment (for treatment failure), repeated screening, limiting screening and treatment to those with the CagA phenotype, or universal treatment, does not appear to be cost-effective. However, most included studies failed to consider both the broader benefits as well as the adverse effects of widespread use of antibiotics for H. pylori. |
| first_indexed | 2025-11-14T09:42:29Z |
| format | Journal Article |
| id | curtin-20.500.11937-49896 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:42:29Z |
| publishDate | 2013 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-498962018-03-29T09:06:50Z Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention Lansdorp_Vogelaar, Iris Sharp, L. Gastric cancer is the second leading cause of cancer-related death worldwide. A meta-analysis of seven randomized controlled trials concluded that Helicobacter pylori eradication reduces gastric cancer incidence by 35%. Current consensus is that H. pylori screening and treatment is cost-effective only in high-risk populations. This paper provides an up-to-date overview of the evidence for cost-effectiveness of H. pylori screening and treatment in different population settings and risk levels for H. pylori infection. Ten unique cost-effectiveness or cost-utility analyses were identified. All found that screening for H. pylori to prevent gastric cancer in the general population costs less than $50,000 per LYG. This finding was robust for differences in H. pylori prevalence, gender and ethnicity. Based on limited evidence, re-treatment (for treatment failure), repeated screening, limiting screening and treatment to those with the CagA phenotype, or universal treatment, does not appear to be cost-effective. However, most included studies failed to consider both the broader benefits as well as the adverse effects of widespread use of antibiotics for H. pylori. 2013 Journal Article http://hdl.handle.net/20.500.11937/49896 10.1016/j.bpg.2013.09.005 restricted |
| spellingShingle | Lansdorp_Vogelaar, Iris Sharp, L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention |
| title | Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention |
| title_full | Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention |
| title_fullStr | Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention |
| title_full_unstemmed | Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention |
| title_short | Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention |
| title_sort | cost-effectiveness of screening and treating helicobacter pylori for gastric cancer prevention |
| url | http://hdl.handle.net/20.500.11937/49896 |